Coenzyme Q headgroup intermediates can ameliorate a mitochondrial encephalopathy

Area of Science:

• Biochemistry
• Neuroscience
• Genetics

Background:

• Decreased brain coenzyme Q10 (CoQ10) levels are linked to neurodegenerative diseases and aging.
• Current CoQ10 supplementation strategies do not effectively increase brain CoQ10 levels.
• The discovery of the HPDL-mediated CoQ10 headgroup synthesis pathway presents a new therapeutic target.

Purpose of the Study:

• To investigate whether 4-hydroxymandelate (4-HMA) and 4-hydroxybenzoate (4-HB) can restore CoQ10 synthesis in vivo.
• To evaluate the therapeutic potential of 4-HMA and 4-HB in a mouse model of CoQ10 deficiency and in a human patient.

Main Methods:

• Administration of 4-HMA and 4-HB to Hpdl-/- mice, a model for primary CoQ10 deficiency.
• Analysis of CoQ9 and CoQ10 levels in the brains of treated mice.
• Assessment of survival rates and neurological symptom improvement in treated mice and a human patient.

Main Results:

• Both 4-HMA and 4-HB were incorporated into CoQ9 and CoQ10 in the brains of Hpdl-/- mice.
• Oral treatment with 4-HMA or 4-HB significantly increased the survival rate of Hpdl-/- mice to adulthood.
• 4-HB treatment stabilized and improved neurological symptoms in a patient with HPDL-related mitochondrial encephalopathy.

Conclusions:

• 4-HMA and 4-HB can serve as precursors to restore CoQ10 synthesis in vivo.
• Supplementation with CoQ10 headgroup intermediates offers a promising therapeutic strategy for HPDL-related mitochondrial encephalopathies.
• This approach demonstrates the potential to pharmacologically address CoQ10 deficiencies by targeting its synthesis pathway.